>Marché européen des maladies rétiniennes héréditaires, par type de maladie (rétinite pigmentaire, maladie de Stargardt, achromatopsie, dystrophie cône-bâtonnet , choroïdérémie, amaurose congénitale de Leber, œdème maculaire et autres), type (diagnostic et thérapie), utilisateur final (hôpitaux, cliniques spécialisées, centres de chirurgie ambulatoire, soins à domicile, autres), canal de distribution (vente au détail et appel d'offres direct) Tendances de l'industrie et prévisions jusqu'en 2029.
Analyse et perspectives du marché : Marché européen des maladies rétiniennes héréditaires
Les maladies rétiniennes héréditaires (ou MRI) sont un groupe de maladies qui peuvent entraîner une perte de vision grave, voire la cécité. Chaque MRI est causée par au moins un gène qui ne fonctionne pas comme il le devrait. Les MRI peuvent toucher des individus de tous âges, peuvent progresser à des rythmes différents et sont rares. Cependant, beaucoup sont dégénératives, ce qui signifie que les symptômes de la maladie s'aggraveront avec le temps. Les types courants de MRI comprennent l'amaurose congénitale de Leber (LCA), la rétinite pigmentaire, la choroïdérémie, la maladie de Stargardt et l'achromatopsie. L'objectif de la thérapie génique est de corriger ou de compenser le gène défectueux. Les MRI sont des candidats particulièrement forts pour les traitements de thérapie génique, en raison de la constitution physique unique de la rétine . Comparé à d'autres organes du corps, l'œil est petit et facile d'accès pour l'administration du traitement. Cependant, certaines zones du corps sont privilégiées sur le plan immunitaire, ce qui signifie que la réponse immunitaire normale n'est pas aussi active. Ce type de greffe se situe généralement dans des zones très importantes de notre corps, qui peuvent être endommagées en cas de gonflement ou d'inflammation. Cela signifie que tout ce qui est implanté dans l'œil (une cellule avec un gène corrigé, par exemple) a moins de chances d'être rejeté.
Le diagnostic et le traitement des maladies rétiniennes héréditaires reposent sur diverses techniques qui permettent de diagnostiquer les maladies rétiniennes héréditaires après l'approbation du produit. Le traitement de la maladie a été récemment approuvé, ce qui soutient la croissance du marché.
Les maladies rétiniennes héréditaires sont favorables et visent à réduire la progression de la maladie. Data Bridge Market Research analyse que le marché des maladies rétiniennes héréditaires connaîtra un TCAC de 9,0 % au cours de la période de prévision de 2022 à 2029.
|
Rapport métrique |
Détails |
|
Période de prévision |
2022 à 2029 |
|
Année de base |
2021 |
|
Années historiques |
2020 (personnalisable de 2019 à 2014) |
|
Unités quantitatives |
Chiffre d'affaires en millions USD, volumes en unités, prix en USD |
|
Segments couverts |
Type de maladie (rétinite pigmentaire, maladie de Stargardt, achromatopsie, dystrophie cône-bâtonnet, choroïdérémie, amaurose congénitale de Leber, œdème maculaire et autres), par type (diagnostic et thérapie), utilisateurs finaux (hôpitaux, cliniques spécialisées, centres de chirurgie ambulatoire, soins à domicile, autres), canal de distribution (vente au détail et appel d'offres direct) |
|
Pays couverts |
Allemagne, France, Royaume-Uni, Russie, Italie, Espagne, Pays-Bas, Suisse, Pologne, Turquie, Autriche, Hongrie, Norvège, Irlande, Lituanie, Reste de l'Europe en Europe |
|
Market Players Covered |
Spark Therapeutics, Novartis AG, Okuvision, Nidek Co. Ltd., Invitae Corporation, Carl Zeiss Meditech AG, Optos (A Subdidiary of Nikon Corporation, Neurosoft, PIXIUM VISION, LKC TECHNOLOGIES, INC., Renurone, Astellas Pharma, REGENXBIO Inc., Ionis Pharmaceutics, Sparing Vision, Ocugen Inc, Johnson & Johnson, IVERIC bio, Second Sight, Coave Therapeutics, MeiraGTx Limited, Gensight Biologics, ProQR Therapeutics, Bionic Vision Technologies |
Inherited Retinal Diseases Market Dynamics
Drivers
- Increase in the Prevalence of Inherited Retinal Diseases
The increasing prevalence and continuous discovery of new mutagenic sites that are genetically transmitted are expected to act as a driver for the growth of the market. The prevalence of monogenic IRDs is approximately 1 in 2000 affecting two million people online.
- Increasing in Pipeline Products
As clinical trial activity rises to new levels, the field appears poised to make rapid and important advances in IRD research and patient care. These are only a few common trials, thus, the companies operating in this market continuously do clinical trials and put their candidates in clinical trials. This is expected to create an opportunity and fuel the Europe inherited retinal diseases market.High prevalence of genetic conditions
Also, the increase in the prevalence rate of some genetic conditions such as Miller-Dieker syndrome and Walker-Warburg syndrome will further enhance the growth of inherited retinal diseases market.
Furthermore, Increase in strategic initiatives by key players, advancement in medical technology, increasing product approval for IRDs, rising initiatives by public and private organizations to spread awareness and growing government funding are the factors that will expand the inherited retinal diseases market. Other factors such as increase in the demand for effective therapies and rising adoption rate for early genetic counselling will positively impact the inherited retinal diseases market's growth rate. Additionally, high disposable income, rising number of cases of various retinal diseases will result in the expansion of inherited retinal diseases market.
Opportunities
- Invrease in Government Initiatives Towards Inherited Retinal Disease.
Moreover, the increase in awareness and treatment seeking rate and emerging reimbursement policies for the treatment will boost new opportunities for the market's growth rate.
Also, the launch of effective therapies and continuous clinical trials will provide beneficial opportunities for the inherited retinal diseases market in the forecast period of 2022-2029. Also, high unmet need of current treatment and developments in healthcare technology will escalate the growth rate inherited retinal diseases market in future.
Restraints/Challenges
Cependant, le coût élevé associé aux traitements disponibles et le manque d’infrastructures dans les pays à faible revenu entraveront le taux de croissance du marché des maladies rétiniennes héréditaires. De plus, le manque de professionnels qualifiés et les complications liées à la maladie entraveront la croissance du marché des maladies rétiniennes héréditaires.
Ce rapport sur le marché des maladies rétiniennes héréditaires fournit des détails sur les nouveaux développements récents, les réglementations commerciales, l'analyse des importations et des exportations, l'analyse de la production, l'optimisation de la chaîne de valeur, la part de marché, l'impact des acteurs du marché national et localisé, les opportunités d'analyse en termes de poches de revenus émergentes, les changements dans la réglementation du marché, l'analyse stratégique de la croissance du marché, la taille du marché, la croissance du marché des catégories, les niches d'application et la domination, les approbations de produits, les lancements de produits, les expansions géographiques, les innovations technologiques sur le marché. Pour obtenir plus d'informations sur le marché des maladies rétiniennes héréditaires, contactez Data Bridge Market Research pour un briefing d'analyste , notre équipe vous aidera à prendre une décision de marché éclairée pour atteindre la croissance du marché.
Analyse épidémiologique des patients
La maladie rétinienne héréditaire est une maladie génétique relativement rare dont l'incidence est inconnue. Selon une étude sur les maladies rétiniennes héréditaires, la prévalence des maladies rétiniennes héréditaires est de 1 sur 3000.
La rétinite pigmentaire est la maladie la plus fréquente parmi les autres maladies. La rétinite pigmentaire est un groupe de maladies oculaires apparentées causées par des variations dans 60 gènes qui affectent la rétine. Les maladies oculaires orphelines sont un groupe hétérogène de maladies oculaires orphelines dont la prévalence est estimée entre 1,0 et 2,5 %, avec un nombre de cas de maladies oculaires orphelines en Europe de l'ordre de 5 à 10 millions de personnes.
Le marché des maladies rétiniennes héréditaires vous fournit également une analyse de marché détaillée pour l'analyse des patients, le pronostic et les remèdes. La prévalence, l'incidence, la mortalité et les taux d'adhésion sont quelques-unes des variables de données disponibles dans le rapport. Les analyses d'impact directes ou indirectes de l'épidémiologie sur la croissance du marché sont analysées pour créer un modèle statistique multivarié de cohorte plus robuste pour prévoir le marché pendant la période de croissance.
Impact post-COVID-19 sur le marché des maladies rétiniennes héréditaires
La COVID-19 a eu un impact négatif sur le marché. Les confinements et l’isolement pendant les pandémies compliquent la gestion de la maladie et l’observance du traitement. Le manque d’accès aux établissements de santé pour le traitement de routine et l’administration des médicaments affectera davantage le marché. L’isolement social augmente le stress, le désespoir et le soutien social, ce qui peut entraîner une réduction de l’observance du traitement anticonvulsivant pendant la pandémie.
Développement récent
- En janvier 2022, certains pays européens ont approuvé la thérapie Luxturan, comme l'Italie, et ont également développé les politiques de remboursement du médicament.
Portée du marché européen des maladies rétiniennes héréditaires
Le marché des maladies rétiniennes héréditaires est segmenté en type de maladie, type, utilisateurs finaux et canal de distribution. La croissance parmi ces segments vous aidera à analyser les segments de croissance faibles dans les industries et à fournir aux utilisateurs un aperçu précieux du marché et des informations sur le marché pour prendre des décisions stratégiques afin d'identifier les principales applications du marché.
Type de maladie
- Rétinite pigmentaire
- Maladie de Stargardt
- Achromatopsie
- Dystrophie cône-bâtonnet
- Choroïdérémie
- Amaurose congénitale de Leber (ACL)
- Œdème maculaire
- Autres
Sur la base du type, le marché des maladies rétiniennes héréditaires est segmenté en type de maladie (rétinite pigmentaire, maladie de Stargardt, achromatopsie, dystrophie cône-bâtonnet, choroïdérémie, amaurose congénitale de Leber, œdème maculaire et autres).
Taper
- Diagnostic
- Thérapie
Sur la base du type, le marché des maladies rétiniennes héréditaires est segmenté en diagnostic et thérapie. Le segment du diagnostic est sous-segmenté en thérapie génique, prothèse rétinienne, agents neuroprotecteurs, autres. Les agents neuroprotecteurs sont en outre sous-segmentés en palmitate de vitamine A, acide docosahexaénoïque (DHA), lutéine, autres. Le segment du diagnostic est segmenté en diagnostic clinique et diagnostic génétique. Le diagnostic clinique est en outre sous-segmenté en imagerie rétinienne, tests électrophysiologiques, test du champ visuel et examen clinique de l'œil. L'imagerie rétinienne est en outre segmentée en tomographie par cohérence optique (OCT), imagerie par autofluorescence du fond d'œil (FAF), ophtalmoscopie laser à balayage (SLO), imagerie par optique adaptative (AO) et imagerie couleur conventionnelle du fond d'œil. Les tests électrophysiologiques sont en outre segmentés en électrorétinogramme plein champ (ERG) et adaptométrie sombre (DA). Le test du champ visuel est en outre segmenté en tests du champ visuel informatisés et test du champ manuel. L'examen clinique des yeux est segmenté en lampe à fente, ophtalmoscopie indirecte, test de réfraction, examen de dilatation
Utilisateur final
- Hôpitaux
- Cliniques spécialisées
- Centre de chirurgie ambulatoire
- Soins à domicile
- Autres
Sur la base des utilisateurs finaux, le marché des maladies rétiniennes héréditaires est segmenté en hôpitaux, cliniques spécialisées, centres chirurgicaux ambulatoires, soins de santé à domicile et autres
Canal de distribution
- Ventes au détail
- Appel d'offres direct
Le marché des maladies rétiniennes héréditaires est également segmenté sur la base du canal de distribution en ventes au détail et appels d'offres directs.
Analyse de pipeline
L'analyse du pipeline des médicaments contre les maladies rétiniennes héréditaires comprend diverses thérapies en pipeline telles que NCT05244304, NCT00999609, NCT05176717, NCT05158296, NCT04850118. Belite Bio, Inc, Spark Therapeutics, ProQR Therapeutics, Applied Genetic Technologies Corp, Biogen, MeiraGTx Ltd sont impliqués dans le développement de médicaments potentiels pour l'amélioration du traitement des crises.
Analyse/perspectives régionales du marché des maladies rétiniennes héréditaires
Le marché des maladies rétiniennes héréditaires est analysé et des informations et tendances sur la taille du marché sont fournies par pays, type de maladie, type, utilisateur final et canal de distribution comme référencé ci-dessus.
The countries covered in the inherited retinal diseases market report are Germany, France, U.K., Russia, Italy, Spain, Netherlands, Switzerland, Poland, Turkey, Austria, Hungary, Norway, Ireland, Lithuania, Rest of Europe in Europe.
Germany dominates the inherited retinal diseases market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the advance technology and product approval in European region.
The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of Europe brands and their challenges faced due to high competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Inherited Retinal Diseases Market Share Analysis
The inherited retinal diseases market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Europe presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on inherited retinal diseases market.
Some of the major players operating in the inherited retinal diseases market are Spark Therapeutics, Novartis AG, Okuvision, Nidek Co. Ltd., Invitae Corporation, Carl Zeiss Meditech AG, Optos (A Subdidiary of Nikon Corporation, Neurosoft, PIXIUM VISION, LKC TECHNOLOGIES, INC., Renurone, Astellas Pharma, REGENXBIO Inc., Ionis Pharmaceutics, Sparing Vision, Ocugen Inc, Johnson & Johnson, IVERIC bio, Second Sight, Coave Therapeutics, MeiraGTx Limited, Gensight Biologics, ProQR Therapeutics, Bionic Vision Technologies among others.
Research Methodology: Europe Inherited Retinal Diseases Market
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des tailles d'échantillon importantes. Les données du marché sont analysées et estimées à l'aide de modèles statistiques et cohérents du marché. En outre, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données, qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). En dehors de cela, les modèles de données comprennent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement de l'entreprise, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse Europe/région et la part des fournisseurs. Veuillez demander un appel d'analyste en cas de demande de renseignements supplémentaires.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE INHERITED RETINAL DISEASES MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PIPELINE ANALYSIS FOR EUROPE INHERITED RETINAL DISEASES MARKET
5 REGULATORY FRAMEWORK
6 PREMIUM INSIGHTS
6.1 PESTEL ANALYSIS
6.2 POTER’S FIVE FORCES MODEL
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASE IN THE PREVALENCE OF INHERITED RETINAL DISEASES
7.1.2 INCREASE IN PIPELINE PRODUCTS
7.1.3 INCREASING PRODUCT APPROVAL FOR INHERITED RETINAL DISEASES
7.1.4 INCREASE IN STRATEGIC INITIATIVE BY KEY PLAYER
7.2 RESTRAINTS
7.2.1 HIGH COST OF TREATMENT AND PROCEDURES
7.2.2 LACK OF ENOUGH QUALIFIED PROFESSIONALS
7.3 OPPORTUNITIES
7.3.1 INCREASE IN GOVERNMENT INITIATIVES TOWARDS INHERITED RETINAL DISEASES(IRDS)
7.3.2 INCREASE IN AWARENESS AND TREATMENT-SEEKING RATE
7.3.3 EMERGING REIMBURSEMENT POLICIES FOR THE TREATMENT
7.4 CHALLENGES
7.4.1 RISKS ASSOCIATED WITH IRD SPECIFIC GENE THERAPY
7.4.2 LIMITED ACCESS TO TREATMENT
8 EUROPE INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE
8.1 OVERVIEW
8.2 RETINITIS PIGMENTOSA
8.3 STARGARDT’S DISEASE
8.4 ACHROMATOPSIA
8.5 CONE-ROD DYSTROPHY
8.6 CHOROIDEREMIA
8.7 LEBER CONGENITAL AMAUROSIS (LCA)
8.8 MACULAR EDEMA
8.9 OTHERS
9 EUROPE INHERITED RETINAL DISEASES MARKET, BY TYPE
9.1 OVERVIEW
9.2 DIAGNOSIS
9.2.1 CLINICAL DIAGNOSIS
9.2.1.1 RETINAL IMAGING
9.2.1.1.1 OPTICAL COHERENCE TOMOGRAPHY (OCT)
9.2.1.1.2 FUNDUS AUTOFLUORESCENCE IMAGING (FAF)
9.2.1.1.3 SCANNING LASER OPHTHALMOSCOPY (SLO)
9.2.1.1.4 ADAPTIVE OPTICS (AO) IMAGING
9.2.1.1.5 CONVENTIONAL COLOR FUNDUS IMAGING
9.2.1.2 ELECTROPHYSIOLOGICAL TESTS
9.2.1.2.1 FULL-FIELD ELECTRORETINOGRAM (ERG)
9.2.1.2.2 DARK ADAPTOMETRY (DA)
9.2.1.3 VISUAL FIELD TEST
9.2.1.3.1 COMPUTERIZED VISUAL FIELD TESTS
9.2.1.3.2 MANUAL FIELD TEST
9.2.1.4 CLINICAL EYE EXAMINATION
9.2.1.4.1 SLIT LAMP
9.2.1.4.2 INDIRECT OPHTHALMOSCOPY
9.2.1.4.3 REFRACTION TEST
9.2.1.4.4 DILATION EXAM
9.2.1.5 OTHERS
9.2.2 GENETIC DIAGNOSIS
9.3 THERAPY
9.3.1 GENE THERAPY
9.3.2 RETINAL PROSTHETIC
9.3.3 NEUROPROTECTIVE AGENTS
9.3.3.1 VITAMIN A PALMITATE
9.3.3.2 DOCOSAHEXAENOIC ACID
9.3.3.3 LUTEIN
9.3.3.4 OTHERS
9.3.4 OTHERS
10 EUROPE INHERITED RETINAL DISEASES MARKET, BY END USER
10.1 OVERVIEW
10.2 HOSPITALS
10.3 SPECIALTY CLINICS
10.4 AMBULATORY SURGICAL CENTERS
10.5 HOME HEALTHCARE
10.6 OTHERS
11 EUROPE INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL
11.1 OVERVIEW
11.2 RETAIL SALES
11.2.1 HOSPITAL PHARMACIES
11.2.2 RETAIL PHARMACIES
11.2.3 OTHERS
11.3 DIRECT TENDER
12 EUROPE INHERITED RETINAL DISEASES MARKET, BY REGION
12.1 EUROPE
12.1.1 GERMANY
12.1.2 FRANCE
12.1.3 U.K.
12.1.4 RUSSIA
12.1.5 ITALY
12.1.6 SPAIN
12.1.7 NETHERLANDS
12.1.8 SWITZERLAND
12.1.9 POLAND
12.1.10 TURKEY
12.1.11 AUSTRIA
12.1.12 HUNGARY
12.1.13 NORWAY
12.1.14 IRELAND
12.1.15 LITHUANIA
12.1.16 REST OF EUROPE
13 EUROPE INHERITED RETINAL DISEASES MARKET: COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: EUROPE
14 SWOT ANALYSIS
15 COMPANY PROFILE
15.1 SPARK THERAPEUTICS, INC.
15.1.1 COMPANY SNAPSHOT
15.1.2 COMPANY SHARE ANALYSIS
15.1.3 PRODUCT PORTFOLIO
15.1.4 RECENT DEVELOPMENTS
15.1.4.1 PROGRAM LAUNCH
15.1.4.2 ACQUISITIONS
15.2 NOVARTIS AG
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENT
15.2.5.1 AGREEMENT
15.3 OKUVISION
15.3.1 COMPANY SNAPSHOT
15.3.2 COMPANY SHARE ANALYSIS
15.3.3 PRODUCT PORTFOLIO
15.3.4 RECENT DEVELOPMENTS
15.3.4.1 EXPANSION
15.3.4.2 EVENTS
15.3.4.3 APPROVAL
15.4 NIDEK CO., LTD
15.4.1 COMPANY SNAPSHOT
15.4.2 COMPANY SHARE ANALYSIS
15.4.3 PRODUCT PORTFOLIO
15.4.4 RECENT DEVELOPMENTS
15.4.4.1 PRODUCT LAUNCH
15.4.4.2 PRODUCT LAUNCH
15.5 INVITAE CORPORATION
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 COMPANY SHARE ANALYSIS
15.5.4 PRODUCT PORTFOLIO
15.5.5 RECENT DEVELOPMENTS
15.5.5.1 PROGRAM LAUNCH
15.5.5.2 ACQUISITION
15.6 ZEISS INTERNATIONAL
15.6.1 COMPANY SNAPSHOT
15.6.2 REVENUE ANALYSIS
15.6.3 PRODUCT PORTFOLIO
15.6.4 RECENT DEVELOPMENTS
15.6.4.1 EVENTS
15.6.4.2 SOCIAL INVOLVEMENT
15.7 OPTOS (A SUBSIDIARY OF NIKON CORPORATION)
15.7.1 COMPANY SNAPSHOT
15.7.2 REVENUE ANALYSIS
15.7.3 PRODUCT PORTFOLIO
15.7.4 RECENT DEVELOPMENTS
15.8 NEUROSOFT
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 RECENT DEVELOPMENTS
15.9 ASTELLAS PHARMA INC.
15.9.1 COMPANY SNAPSHOT
15.9.2 REVENUE ANALYSIS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT DEVELOPMENTS
15.1 BIONIC VISION TECHNOLOGIES
15.10.1 COMPANY SNAPSHOT
15.10.2 PRODUCT PORTFOLIO
15.10.3 RECENT DEVELOPMENT
15.10.3.1 AWARD
15.11 COAVE THERAPEUTICS
15.11.1 COMPANY SNAPSHOT
15.11.2 PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENT
15.11.3.1 AGREEMENT
15.12 GENSIGHT BIOLOGICS
15.12.1 COMPANY SNAPSHOT
15.12.2 REVENUE ANALYSIS
15.12.3 PRODUCT PORTFOLIO
15.12.4 RECENT DEVELOPMENTS
15.12.4.1 EVENT
15.12.4.2 AWARD
15.13 IONIS PHARMACEUTICALS
15.13.1 COMPANY SNAPSHOT
15.13.2 REVENUE ANALYSIS
15.13.3 PRODUCT PORTFOLIO
15.13.4 RECENT DEVELOPMENT
15.13.4.1 EVENT
15.14 IVERIC BIO
15.14.1 COMPANY SNAPSHOT
15.14.2 PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENTS
15.15 JOHNSON &JOHNSON SERVICES, INC.
15.15.1 COMPANY SNAPSHOT
15.15.2 REVENUE ANALYSIS
15.15.3 PRODUCT PORTFOLIO
15.15.4 RECENT DEVELOPMENT
15.15.4.1 COLLABORATION
15.16 LKC TECHNOLOGIES, INC.
15.16.1 COMPANY SNAPSHOT
15.16.2 PRODUCT PORTFOLIO
15.16.3 RECENT DEVELOPMENT
15.16.3.1 PRODUCT LAUNCH
15.17 MEIRAGTX LIMITED
15.17.1 COMPANY SNAPSHOT
15.17.2 PRODUCT PORTFOLIO
15.17.3 RECENT DEVELOPMENTS
15.17.3.1 EVENTS
15.17.3.2 AWARD
15.17.3.3 COLLABORATION
15.18 OCUGEN INC.
15.18.1 COMPANY SNAPSHOT
15.18.2 PRODUCT PORTFOLIO
15.18.3 RECENT DEVELOPMENTS
15.18.3.1 INVESTMENT
15.18.3.2 CLINICAL TRIAL
15.19 PIXIUM VISION
15.19.1 COMPANY SNAPSHOT
15.19.2 REVENUE ANALYSIS
15.19.3 PRODUCT PORTFOLIO
15.19.4 RECENT DEVELOPMENT
15.19.4.1 AWARD
15.2 PROQR THERAPEUTICS
15.20.1 COMPANY SNAPSHOT
15.20.2 PRODUCT PORTFOLIO
15.20.3 RECENT DEVELOPMENT
15.20.3.1 EVENT
15.21 SECOND SIGHT
15.21.1 COMPANY SNAPSHOT
15.21.2 PRODUCT PORTFOLIO
15.21.3 RECENT DEVELOPMENT
15.21.3.1 PRODUCT LAUNCH
15.22 SPARING VISION
15.22.1 COMPANY SNAPSHOT
15.22.2 PRODUCT PORTFOLIO
15.22.3 RECENT DEVELOPMENT
15.22.3.1 ACQUISITION
15.23 REGENXBIO INC.
15.23.1 COMPANY SNAPSHOT
15.23.2 PRODUCT PORTFOLIO
15.23.3 RECENT DEVELOPMENTS
15.23.3.1 EVENT
15.23.3.2 COLLABORATION
15.23.3.3 CERTIFICATION
15.24 RENEURON GROUP PLC
15.24.1 COMPANY SNAPSHOT
15.24.2 PRODUCT PORTFOLIO
15.24.3 RECENT DEVELOPMENT
15.24.3.1 STRATEGIC INITIATIVE
16 QUESTIONNAIRE
17 RELATED REPORTS
Liste des tableaux
TABLE 1 PIPELINE ANALYSIS FOR INHERITED RETINAL DISEASES:
TABLE 2 EUROPE INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 3 EUROPE RETINITIS PIGMENTOSA IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 EUROPE STARGARDT’S DISEASE IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 EUROPE ACHROMATOPSIA IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 EUROPE CONE-ROD DYSTROPHY IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 EUROPE CHOROIDERMIA IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 EUROPE LEBER CONGENITAL AMAUROSIS (LCA) IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 9 EUROPE MACULAR EDEMA IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 EUROPE OTHERS IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 EUROPE INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 12 EUROPE DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 EUROPE DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 14 EUROPE CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 15 EUROPE RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 16 EUROPE ELECTROPHYSIOLOGICAL TETS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 17 EUROPE VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 18 EUROPE CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 19 EUROPE THERAPY IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 EUROPE THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 21 EUROPE NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 22 EUROPE INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 23 EUROPE HOSPITALS IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 EUROPE SPECIALTY CLINICS IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 25 EUROPE AMBULATORY SURGICAL CENTERS IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 EUROPE HOME HEALTHCARE IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 EUROPE OTHERS IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 EUROPE INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 29 EUROPE RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 EUROPE RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 31 EUROPE DIRECT TENDER IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 EUROPE INHERITED RETINAL DISEASES MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 33 EUROPE INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 34 EUROPE INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 35 EUROPE THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 36 EUROPE NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 37 EUROPE DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 38 EUROPE CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 39 EUROPE RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 40 EUROPE ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 41 EUROPE VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 42 EUROPE CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 43 EUROPE INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 44 EUROPE INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 45 EUROPE RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 46 GERMANY INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 47 GERMANY INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 48 GERMANY THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 49 GERMANY NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 50 GERMANY DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 51 GERMANY CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 52 GERMANY RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 53 GERMANY ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 54 GERMANY VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 55 GERMANY CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 56 GERMANY INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 57 GERMANY INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 58 GERMANY RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 59 FRANCE INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 60 FRANCE INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 61 FRANCE THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 62 FRANCE NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 63 FRANCE DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 64 FRANCE CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 65 FRANCE RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 66 FRANCE ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 67 FRANCE VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 68 FRANCE CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 69 FRANCE INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 70 FRANCE INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 71 FRANCE RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 72 U.K. INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 73 U.K. INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 74 U.K. THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 75 U.K. NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 76 U.K. DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 77 U.K. CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 78 U.K. RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 79 U.K. ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 80 U.K. VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 81 U.K. CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 82 U.K. INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 83 U.K. INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 84 U.K. RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 85 RUSSIA INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 86 RUSSIA INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 87 RUSSIA THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 88 RUSSIA NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 89 RUSSIA DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 90 RUSSIA CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 91 RUSSIA RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 92 RUSSIA ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 93 RUSSIA VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 94 RUSSIA CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 95 RUSSIA INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 96 RUSSIA INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 97 RUSSIA RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 98 ITALY INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 99 ITALY INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 100 ITALY THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 101 ITALY NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 102 ITALY DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 103 ITALY CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 104 ITALY RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 105 ITALY ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 106 ITALY VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 107 ITALY CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 108 ITALY INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 109 ITALY INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 110 ITALY RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 111 SPAIN INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 112 SPAIN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 113 SPAIN THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 114 SPAIN NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 115 SPAIN DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 116 SPAIN CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 117 SPAIN RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 118 SPAIN ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 119 SPAIN VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 120 SPAIN CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 121 SPAIN INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 122 SPAIN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 123 SPAIN RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 124 NETHERLANDS INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 125 NETHERLANDS INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 126 NETHERLANDS THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 127 NETHERLANDS NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 128 NETHERLANDS DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 129 NETHERLANDS CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 130 NETHERLANDS RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 131 NETHERLANDS ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 132 NETHERLANDS VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 133 NETHERLANDS CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 134 NETHERLANDS INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 135 NETHERLANDS INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 136 NETHERLANDS RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 137 SWITZERLAND INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 138 SWITZERLAND INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 139 SWITZERLAND THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 140 SWITZERLAND NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 141 SWITZERLAND DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 142 SWITZERLAND CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 143 SWITZERLAND RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 144 SWITZERLAND ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 145 SWITZERLAND VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 146 SWITZERLAND CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 147 SWITZERLAND INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 148 SWITZERLAND INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 149 SWITZERLAND RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 150 POLAND INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 151 POLAND INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 152 POLAND THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 153 POLAND NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 154 POLAND DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 155 POLAND CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 156 POLAND RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 157 POLAND ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 158 POLAND VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 159 POLAND CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 160 POLAND INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 161 POLAND INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 162 POLAND RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 163 TURKEY INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 164 TURKEY INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 165 TURKEY THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 166 TURKEY NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 167 TURKEY DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 168 TURKEY CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 169 TURKEY RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 170 TURKEY ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 171 TURKEY VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 172 TURKEY CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 173 TURKEY INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 174 TURKEY INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 175 TURKEY RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 176 AUSTRIA INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 177 AUSTRIA INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 178 AUSTRIA THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 179 AUSTRIA NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 180 AUSTRIA DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 181 AUSTRIA CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 182 AUSTRIA RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 183 AUSTRIA ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 184 AUSTRIA VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 185 AUSTRIA CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 186 AUSTRIA INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 187 AUSTRIA INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 188 AUSTRIA RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 189 HUNGARY INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 190 HUNGARY INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 191 HUNGARY THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 192 HUNGARY NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 193 HUNGARY DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 194 HUNGARY CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 195 HUNGARY RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 196 HUNGARY ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 197 HUNGARY VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 198 HUNGARY CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 199 HUNGARY INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 200 HUNGARY INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 201 HUNGARY RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 202 NORWAY INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 203 NORWAY INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 204 NORWAY THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 205 NORWAY NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 206 NORWAY DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 207 NORWAY CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 208 NORWAY RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 209 NORWAY ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 210 NORWAY VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 211 NORWAY CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 212 NORWAY INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 213 NORWAY INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 214 NORWAY RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 215 IRELAND INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 216 IRELAND INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 217 IRELAND THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 218 IRELAND NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 219 IRELAND DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 220 IRELAND CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 221 IRELAND RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 222 IRELAND ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 223 IRELAND VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 224 IRELAND CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 225 IRELAND INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 226 IRELAND INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 227 IRELAND RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 228 LITHUANIA INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 229 LITHUANIA INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 230 LITHUANIA THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 231 LITHUANIA NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 232 LITHUANIA DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 233 LITHUANIA CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 234 LITHUANIA RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 235 LITHUANIA ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 236 LITHUANIA VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 237 LITHUANIA CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 238 LITHUANIA INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 239 LITHUANIA INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 240 LITHUANIA RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 241 REST OF EUROPE INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
Liste des figures
FIGURE 1 EUROPE INHERITED RETINAL DISEASES MARKET: SEGMENTATION
FIGURE 2 EUROPE INHERITED RETINAL DISEASES MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE INHERITED RETINAL DISEASES MARKET: DROC ANALYSIS
FIGURE 4 EUROPE INHERITED RETINAL DISEASES MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE INHERITED RETINAL DISEASES MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE INHERITED RETINAL DISEASES MARKET: MULTIVARIATE MODELLING
FIGURE 7 EUROPE INHERITED RETINAL DISEASES MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 EUROPE INHERITED RETINAL DISEASES MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE INHERITED RETINAL DISEASES MARKET: MARKET END USER COVERAGE GRID
FIGURE 10 EUROPE INHERITED RETINAL DISEASES MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 EUROPE INHERITED RETINAL DISEASES MARKET: SEGMENTATION
FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE AND EUROPE IS GROWING AT THE FASTEST PACE IN EUROPE INHERITED RETINAL DISEASES MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 13 INCREASE IN THE PREVALENCE OF INHERITED RETINAL DISEASES AND INCREASE IN PIPELINE PRODUCTS ARE DRIVING THE EUROPE INHERITED RETINAL DISEASES MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 14 RETINITIS PIGMENTOSA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE INHERITED RETINAL DISEASES MARKET IN 2022 & 2029
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE INHERITED RETINAL DISEASES MARKET
FIGURE 16 EUROPE INHERITED RETINAL DISEASES MARKET: BY DISEASE TYPE, 2021
FIGURE 17 EUROPE INHERITED RETINAL DISEASES MARKET: BY DISEASE TYPE, 2020-2029 (USD MILLION)
FIGURE 18 EUROPE INHERITED RETINAL DISEASES MARKET: BY DISEASE TYPE, CAGR (2022-2029)
FIGURE 19 EUROPE INHERITED RETINAL DISEASES MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 20 EUROPE INHERITED RETINAL DISEASES MARKET: BY TYPE, 2021
FIGURE 21 EUROPE INHERITED RETINAL DISEASES MARKET: BY TYPE, 2020-2029 (USD MILLION)
FIGURE 22 EUROPE INHERITED RETINAL DISEASES MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 23 EUROPE INHERITED RETINAL DISEASES MARKET: BY TYPE, LIFELINE CURVE
FIGURE 24 EUROPE INHERITED RETINAL DISEASES MARKET: BY END USER, 2021
FIGURE 25 EUROPE INHERITED RETINAL DISEASES MARKET: BY END USER, 2020-2029 (USD MILLION)
FIGURE 26 EUROPE INHERITED RETINAL DISEASES MARKET: BY END USER, CAGR (2022-2029)
FIGURE 27 EUROPE INHERITED RETINAL DISEASES MARKET: BY END USER, LIFELINE CURVE
FIGURE 28 EUROPE INHERITED RETINAL DISEASES MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 29 EUROPE INHERITED RETINAL DISEASES MARKET: BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
FIGURE 30 EUROPE INHERITED RETINAL DISEASES MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 31 EUROPE INHERITED RETINAL DISEASES MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 32 EUROPE INHERITED RETINAL DISEASES MARKET: SNAPSHOT (2021)
FIGURE 33 EUROPE INHERITED RETINAL DISEASES MARKET: BY COUNTRY (2021)
FIGURE 34 EUROPE INHERITED RETINAL DISEASES MARKET: BY COUNTRY (2022 & 2029)
FIGURE 35 EUROPE INHERITED RETINAL DISEASES MARKET: BY COUNTRY (2021 & 2029)
FIGURE 36 EUROPE INHERITED RETINAL DISEASES MARKET: BY DISEASE TYPE (2022-2029)
FIGURE 37 EUROPE INHERITED RETINAL DISEASES MARKET: COMPANY SHARE 2021 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
